Skip to main content

PRONTO-PEDS

A prospective, randomized, double-blind comparison of LY900014 to insulin Lispro with an open-label postprandial LY900014 treatment group in children and adolescents with Type 1 diabetes (PRONTO-Peds) | NCT03740919

PRONTO-PEDS

Associated Conditions

TYPE 1 DIABETESDiabetes

Principal Investigator

Sponsor

Lilly USA, LLC

This study is being done to compare an ultra rapid acting insulin, LY900014 and Humalog with regards to glycemic control in children and adolescents with type 1 diabetes.  This will be measured by change in hemoglobin A1c from baseline to week 26 when insulin is administered in a double-blind manner as prandial insulin in combination with basal insulin.

This study is currently enrolling.